Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003542-21
    Sponsor's Protocol Code Number:ALADDIN
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2024-09-19
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-003542-21
    A.3Full title of the trial
    Evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
    Évaluation de l’ajout du darolutamide à l’hormonothérapie et à la radiothérapie chez des patients atteints d’un cancer de prostate avec des métastases ganglionnaires pelviennes.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial evaluating dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.
    Etude de phase III randomisée multicentrique contrôlée contre placebo évaluant l’ajout du darolutamide à l’hormonothérapie et à la radiothérapie chez des patients atteints d’un cancer de prostate avec des métastases ganglionnaires pelviennes.
    A.3.2Name or abbreviated title of the trial where available
    ALADDIN
    ALADDIN
    A.4.1Sponsor's protocol code numberALADDIN
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportBAYER
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    B.5.2Functional name of contact pointSponsor
    B.5.3 Address:
    B.5.3.1Street AddressHôpital Européen Georges Pompidou Oncologie Médicale, 20-40, rue Leblanc,
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75015
    B.5.3.4CountryFrance
    B.5.4Telephone number+330156 09 50 16
    B.5.5Fax number+330156 09 24 31
    B.5.6E-mailmouna.rouabah-ext@aphp.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name NUBEQA
    D.2.1.1.2Name of the Marketing Authorisation holderBAYER
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDAROLUTAMIDE
    D.3.2Product code NUBEQA
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Prostate cancer with pelvic lymph nodes metastases.
    Cancer de la prostate avec des métastases ganglionnaires pelviennes.
    E.1.1.1Medical condition in easily understood language
    Prostate cancer with pelvic lymph nodes metastases.
    Cancer de la prostate avec des métastases ganglionnaires pelviennes.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the impact of Darolutamide in addition to ADT and Radiotherapy on the failure-free survival (FFS) in patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases.
    Évaluer l’impact du Darolutamide avec la RTHT sur la survie sans récidive à 3 ans chez des patients présentant un cancer de prostate avec des métastases ganglionnaires pelviennes.
    E.2.2Secondary objectives of the trial
    Evaluate:
    1. Failure-free survival rates at 3 years
    2. Metastasis-free survival and Metastasis-free survival rates at 3 years
    3. Progression-free survival and Progression-free survival rates at 3 years
    4. Time to PSA response, Time to PSA progression and PSA response rate (30%, 50%, 90%, undetectable = 0.2 ng/mL), PSA at 6 months after completion of radiotherapy and PSA ≥0.1 ng/mL at 6 months after completion of radiotherapy
    5. Overall survival and Survival rates at 3 years
    6. Cancer-specific survival and Cancer-specific survival rates
    7. Time to pain progression (EVA scale)
    8. Toxicities (CTCAE v5.0)
    9. Quality of life ( EORTC QLQ-C302 and QLQ-PR25)

    Évaluer :
    1. Taux de survie sans récidive à 3 ans
    2. Taux de survie sans métastase et taux de survie sans métastase à 3 ans
    3. Survie sans progression et taux de survie sans progression à 3 ans
    4. Temps de réponse au PSA, temps de progression du PSA et taux de réponse
    au PSA (30 %, 50 %, 90 %, indétectable = 0,2 ng/mL), PSA à 6 mois après la fin
    de la radiothérapie et PSA ≥0,1 ng/mL à 6 mois après la fin de la radiothérapie.
    5. Survie globale et taux de survie à 3 ans
    6. Survie spécifique au cancer et taux de survie spécifique au cancer
    7. Délai de progression de la douleur (échelle EVA)
    8. Toxicités (CTCAE v5.0)
    9. Qualité de vie (EORTC QLQ-C30 et QLQ-PR25)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Newly diagnosed, histologically confirmed prostate adenocarcinoma
    2. ≥ 18 years old.
    3. Initial staging with Pelvic MRI + (contrast-enhanced body CT-scan + bone scan or
    Choline or PSMA PET-CT)
    4. Any T stage
    5. N stage: N1 - Pelvis lymph nodes metastases (upper limit defined as the L4/L5
    interspace).
    6. Intention to treat with long-term androgen deprivation therapy (24 months).
    7. Hormonal therapy with LHRH agonist or antagonist is allowed up to 3 months prior
    to treatment initiation.
    8. Able to receive protocol therapy and have life expectancy of at least 36 months,
    ECOG Performance Status (PS) 0-2.
    9. Blood counts at screening: hemoglobin ≥ 9.0 g/dl, absolute neutrophil count ≥ 1500/μl
    (1.5x109/l), platelet count ≥ 100,000/μl (100x109/l ) (patient must not have received
    any growth factor or blood transfusion within 7 days of the hematology laboratory
    obtained at screening).
    ARTIC - Clinical Study Protocol ALADDIN GETUG P17
    Edition Number 4.0
    Date June 13th, 2024
    9/44
    RESTRICTED
    10. Screening values of serum alanine aminotransferase (ALT) and/or aspartate
    transaminase (AST) < 2.5 x upper limit of normal (ULN), total bilirubin < 1.5 x ULN
    (except patients with a diagnosis of Gilbert’s disease), creatinine < 2.0 x ULN.
    11. Sexually active patients, unless surgically sterile, must agree to use condoms as an
    effective barrier method during the study treatment and for 3 months after the end of
    the study treatment.
    12. Written informed consent.
    13. Willing and expected to comply with follow-up schedule.
    14. Affiliated to the social security system.
    15. Use of 5-α reductase inhibitors (finasteride, dutasteride) is allowed

    1. Adénocarcinome de prostate histologiquement prouvé et récemment
    diagnostiqué
    2. Age ≥ 18 ans
    3. Bilan initial comprenant une IRM pelvienne, une TEP Choline ou PMSA ou un
    scanner thoraco-abdomino-pelvien+ scintigraphie osseuse.
    4. Tout stade T.
    5. Stade N : N1 métastases ganglionnaires pelviennes (limite supérieur définie
    L4/L5).
    6. Intension de traiter avec une hormonothérapie longue de 24 mois.
    7. L’hormonothérapie avec agoniste ou antagoniste de la LH-RH est autorisée
    jusqu’à 3 mois avant le début de traitement
    8. En mesure de recevoir un protocole thérapeutique et ayant une espérance de
    vie d'au moins 36 mois, ECOG Performance Status (PS) 0-2
    9. Avoir réalisé le bilan nécessaire avant la randomisation NFS : hémoglobine ≥
    9.0 g/dL, neutrophiles ≥ 1500/μL (1.5x109/L), plaquettes ≥ 100,000/μL
    (100x109/L) (les patients ne doivent avoir reçu ni facteurs de croissance ni
    transfusion dans les 7 jours précédant les examens hématologiques de
    screening).
    10. Bilan biologique : ALAT et /ou ASAT< 2.5x limite supérieure à la normale,
    bilirubine totale < 1.5 limite supérieure à la normale (sauf maladie de Gilbert),
    créatinine < 2.0 x limite supérieure à la normale.
    11. Patients actifs sexuellement, à l’exception de ceux qui sont stériles après
    chirurgie, doivent accepter d’utiliser un préservatif jusque 3 mois après la fin du
    traitement.
    12. Consentement écrit et signé.
    13. Accepte de réaliser le protocole de suivi.
    14. Affilié à la sécurité sociale.
    15. L’utilisation d’inhibiteurs de la 5-α réductase (finastéride, dutastéride) est
    autorisée.
    E.4Principal exclusion criteria
    1. Lymph nodes metastases outside of the pelvis
    2. Bone or visceral metastases
    3. Prior systemic therapy for locally-advanced prostate cancer except for LHRH agonist
    or antagonist up to 3 months before treatment initiation
    4. Prior treatment with:
    - Second generation AR inhibitors such as enzalutamide, apalutamide (ARN-509),
    darolutamide (ODM-201) other investigational AR inhibitors
    - CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
    - Oral ketoconazole
    - Use of estrogens, or AR inhibitors (bicalutamide = Casodex©, flutamide, nilutamide,
    cyproterone acetate) within 28 days before treatment initiation.
    5. Use of systemic corticosteroid with dose greater than the equivalent 10 mg of
    prednisone/day within 28 days before treatment initiation.
    6. Patients with QTor QTc interval > 450 ms on the ECG
    7. Initiation of treatment with bisphosphonate or denosumab within 12 weeks before
    treatment initiation. Patients receiving bone loss prevention treatment on a stable
    dose of e.g. bisphosphonate or denosumab for at least 28 days before treatment
    initiation can continue the treatment during the study.
    8. Known hypersensitivity to the study treatment (RT, ADT, darolutamide/placebo) or
    any of its ingredients.
    9. Major surgery within 28 days before treatment initiation.
    10. Any of the following within 6 months before treatment initiation: stroke, myocardial
    infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft;
    congestive heart failure New York Heart Association (NYHA) Class III or IV or arterial
    thromboembolic event.
    11. Uncontrolled hypertension as indicated by a resting systolic BP > 160 mmHg or
    diastolic BP > 100 mmHg at screening. Patients may be re-screened after
    adjustments of anti- hypertensive medications.
    12. Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin
    or superficial bladder cancer that has not spread behind the connective tissue layer
    (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which
    chemotherapy has been completed > 5 years ago and from which the patient has
    been disease-free.
    13. Gastrointestinal disorder or procedure which expects to interfere significantly with
    absorption of study treatment.
    14. Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver
    disease.
    15. Participation in another interventional clinical trial and any concurrent treatment with
    any investigational drug
    16. Any condition that in the opinion of the investigator would impair the patients’ ability
    to comply with the study procedures.
    17. Unable to swallow study medications and comply with study requirements.
    18. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose
    malabsorption
    19. History of bilateral hip replacements making IMRT impossible
    20. Contra-indications for the administration of any of the study treatments (RT, ADT,
    darolutamide/placebo) or any of its ingredients.
    21. Patient under guardianship, administrative curatorship and not able to give informed
    consent
    1. Métastases ganglionnaires extra-pelvienne.
    2. Métastases osseuses ou viscérales.
    3. Traitement systémique antérieur contre le cancer de prostate localement
    avancé, à l’exception de l’agoniste ou de l’antagoniste de la LH-RH jusqu’à 3
    mois avant le début de traitement
    4. Traitements antérieurs :
    - Inhibiteurs des récepteurs aux androgènes de seconde génération comme
    l'enzalutamide, apalutamide (ARN-509), le darolutamide (ODM-201) ou
    d’autres inhibiteurs expérimentaux
    - Inhibiteur de l’enzyme CYP17 tels que l’acétate d’abiratérone, le TAK 700
    - Le kétoconazole par voie orale
    - L’utilisation d’œstrogènes ou d’inhibiteurs de AR (bicalutamide =
    CasodexÓ), flutamide, nilutamide, cyproterone acetate) dans les 28 jours
    avant le début de traitement.
    5. Utilisation corticostéroïdes à une dose supérieure à 10 mg d’équivalent de
    prednisone par jour dans les 28 jours précédant le début de traitement.
    6. Patients présentant un intervalle QT ou QTc > 450 ms sur
    l'électrocardiogramme.
    7. Initiation d’un traitement par les biphosphonates ou de denosumab dans les 12
    semaines précédant le début de traitement Les patients recevant déjà ces
    traitements de prévention de la perte osseuse à une dose stable depuis au
    moins 28 jours avant le début de traitement peuvent poursuivre le traitement
    pendant l’étude.
    8. Hypersensibilité connue aux traitements de l’étude (RT, HT, darutolamide,
    placebo) ou un de ses traitements.
    9. Chirurgie majeure dans les 28 jours précédant le début de traitement.
    10. Dans les 6 mois précédant le début de traitement: AVC, infarctus du myocarde,
    angine de poitrine grave/instable, syndrome coronarien aigue, pontage
    coronarien, insuffisance cardiaque stade III ou IV NYHA ou événement
    thromboembolique artériel.
    11. Hypertension non-contrôlée (systolique > 160 mmHg ou diastolique > 100
    mmHg) au screening.
    Les patients peuvent être rescreenés après équilibration par des médicaments
    hypertenseurs
    12. Cancer antérieur : les carcinomes baso-cellulaires cutanés ou les carcinomes
    épidermoïdes superficiels de vessie (c'est-à-dire pTis, pTa et pT1) sont
    autorisés, tout autre cancer pour lequel la chimiothérapie a été achevée il y a
    plus de 5 ans et dont le patient n'a pas souffert.
    13. Maladie ou chirurgie gastro-intestinale empêchant l’absorption adéquate du
    traitement.
    14. Hépatite virale active, VIH actif, maladie hépatique chronique.
    15. Participation à une autre étude interventionnelle.
    16. Toute pathologie qui empêche l’inclusion du patient selon l’investigateur.
    17. Incapacité à avaler le médicament.
    18. Intolérance au galactose, déficit en lactase de Lapp ou malabsorption du
    glucose-galactose.
    19. Antécédents de prothèse de hanche bilatérale empêchant la réalisation d’une
    radiothérapie avec modulation d’intensité.
    20. Contre-indication à la prise de l’un des traitements de l’étude (radiothérapie,
    hormonothérapie, darolutamide ou placebo) ou de l’un de ces traitements.
    21. Patients sous tutelle ou en incapacité de donner leur consentement
    E.5 End points
    E.5.1Primary end point(s)
    The failure-free survival is defined as the time from the date of randomization to clinical (new cancer-related symptoms), biochemical (PSA rising above nadir + 2ng/mL, phoenix criteria) or radiological (local relapse or new metastases) progression, death, end of 3-year follow-up period or lost to follow-up, whichever occurs first.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Medical visit every 3 months for the first year and then every 6 months until the end of the trial.

    Blood samples (laboratory safety assessments) wil be taken before each visit = controling PSA level

    CT scan+ bone scan every 3 months the first year and every 6 months until the end of study.

    Visite médicale chaque 3 mois la première année puis chaque 6 mois jusqu'à la fin d'essai.

    Les échantillons sanguins seront prélevés avant chaque visite = contrôle du niveau de PSA.

    CT scan+ scintigraphie osseuse tous les 3 mois la première année puis tous les 6 mois jusqu'à la fin de l'étude.

    E.5.2Secondary end point(s)
    Failure-free survival rates at 3 years.
    • Metastasis-free survival and Metastasis-free survival rates at 3 years : Metastasis-free survival
    is defined as the time from the date of treatment initiation to the date of increase in the number
    of metastatic pelvic lymph nodes, or death due to any cause, whichever is first.
    • Progression-free survival and Progression-free survival rates at 3 years : Progression free
    survival is defined as the time from the date of treatment initiation to disease progression or death
    from any whichever is first. A progression is defined by radiological progression or biological
    progression or a clinical progression.
    • Time to PSA response, Time to PSA progression defined as the time from baseline to the date
    of biochemical relapse as defined by the Phoenix criteria (increase of 2 ng/mL from nadir). PSA
    response rate (30%, 50%, 90%, undetectable = 0.2 ng/mL). PSA response is defined by the rate
    of patients having a decrease of > 30%, 50%, 90% or undetectable (0.2ng/mL) of their PSA level
    from baseline, as measured every 3 months. PSA at 6 months after completion of radiotherapy
    and PSA ≥0.1 ng/mL at 6 months after completion of radiotherapy.
    • Overall survival and Survival rates at 3 years. Overall survival is defined as the time from
    treatment initiation to the date of documented death from any cause.
    • Cancer-specific survival and Cancer-specific survival rates. Cancer-specific survival is defined
    as the time from treatment initiation to the date of documented death from prostate cancer or
    complication from the treatment, whichever occurs first.
    • Time to pain progression (EVA scale)
    • Toxicities (CTCAE v5.0)
    • Quality of life ( EORTC QLQ-C302 and QLQ-PR253)
    E.5.2.1Timepoint(s) of evaluation of this end point
    CT scan+ bone scan every 3 months the first year and every 6 months until the end of study.

    Blood samples (laboratory safety assessments) wil be taken before each visit = controling PSA level

    Time to pain progression will be evaluated at every visit.

    AEs will be evaluated at every visit and graded according to National
    Cancer Institute Common Terminology Criteria for Adverse Events (NCI
    CTCAE) version 5.0.

    Quality of life will be assessed using self-administered questionnaires (EORTC QLQ-C302 and EORTC QLQ-PR253) will be evaluated at every visit.
    CT scan+ scintigraphie osseuse tous les 3 mois la première année puis tous les 6 mois jusqu'à la fin de l'étude.

    Des échantillons sanguins seront prélevés avant chaque visite = contrôle du niveau de PSA.

    Le temps jusqu'à la progression de la douleur sera évalué à chaque visite.

    Les effets indésirables seront évalués à chaque visite et classés selon les critères communs de terminologie du National Cancer Institute pour les effets indésirables.
    Cancer Institute Common Terminology Criteria for Adverse Events (NCI
    CTCAE) version 5.0.

    La qualité de vie sera évaluée à l'aide de questionnaires auto-administrés (EORTC QLQ-C302 et EORTC QLQ-PR253) à chaque visite.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned27
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will end after the last patient included completed all the
    evaluations required
    La fin de l'étude correspond à la dernière visite du dernier patient
    inclus.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 76
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 76
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state152
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-01-11
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 09:15:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA